PAINREFORM LTD. Logo

PAINREFORM LTD.

Specialty pharma developing extended-release drugs for post-operative pain management.

PRFX | US

Overview

Corporate Details

ISIN(s):
IL0011651580
LEI:
Country:
United States of America
Address:
65 YIGAL ALON ST., 6744316 TEL AVIV
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

PainReform Ltd. is a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics for improved pain management. The company develops treatments using its proprietary extended-release drug-delivery system, designed to prolong efficacy, reduce adverse effects, and increase patient comfort. Its lead product candidate, PRF-110, is an oil-based solution that is instilled directly into a surgical wound to provide localized and extended post-operative analgesia. This approach aims to reduce the need for systemically administered opiates. The company is also strategically expanding its drug delivery platform into other therapeutic areas, such as ophthalmology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all PAINREFORM LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PAINREFORM LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PAINREFORM LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Monopar Therapeutics Logo
Clinical-stage biotech developing radiopharmaceuticals for oncology and therapies for rare diseases.
United States of America
MNPR
Monte Rosa Therapeutics, Inc. Logo
Develops molecular glue degraders to target undruggable proteins in cancer and immune diseases.
United States of America
GLUE
Develops LNP drug delivery systems for severe diseases, offering R&D to GMP manufacturing support.
South Korea
322970
MORISHITA JINTAN CO.,LTD. Logo
Manufactures health products and provides OEM/ODM services using advanced encapsulation technology.
Japan
4524
MUROMACHI CHEMICALS INC. Logo
A diversified manufacturer of pharmaceuticals, chemical systems, health foods & functional materials.
Japan
4885
MUSTANG BIO, INC. Logo
Developing CAR T-cell and gene therapies for cancers and rare genetic disorders.
United States of America
MBIO
MYUNGMOON PHARM CO.,LTD Logo
Develops, manufactures, and commercializes prescription & OTC medicines for global markets.
South Korea
017180
Nanexa AB Logo
Develops long-acting injectables using its proprietary nanotechnology for its own pipeline and partners.
Sweden
NANEXA
Nanobiotix Logo
Develops a first-in-class radioenhancer to amplify radiotherapy's effect directly within tumors.
France
NANO
Nanobiotix S.A. Logo
Developing a nanotherapeutic radioenhancer that amplifies radiation to destroy solid tumors.
United States of America
NBTX

Talk to a Data Expert

Have a question? We'll get back to you promptly.